State amici warn FTC-led suit against WPATH could reshape clinical guidelines oversight

Seventeen states and the District of Columbia filed an amicus brief supporting the World Professional Association for Transgender Health (WPATH) and the United States Professional Association for Transgender Health (USPATH) in a consumer protection lawsuit brought by the Federal Trade Commission (FTC) and the states of Alaska, Iowa, Nebraska, and Texas. The amici argue that the plaintiffs’ theory could extend beyond transgender healthcare by subjecting professional medical guidelines to federal consumer protection scrutiny. On August 14, 2026, the US District Court for the Northern District of Texas accepted the brief and denied the FTC’s motion to strike it.

The lawsuit, Federal Trade Commission, et al. v. World Professional Association for Transgender Health Inc., et al., is currently pending in the district court. WPATH is an interdisciplinary professional and educational organization devoted to transgender health that publishes standards of care and ethical guidelines. The plaintiffs allege that WPATH made false, misleading, or unsubstantiated claims in its current standards of care guidelines (SOC-8) and related materials about the medical consensus, medical necessity, safety, and effectiveness of gender-affirming care for minors. The FTC further alleges that WPATH supplied clinicians with the “means and instrumentalities” to repeat those claims to patients and parents and induce the purchase of medical services, in violation of Sections 5 and 12 of the FTC Act and state consumer protection laws.

WPATH disputes that characterization, arguing that SOC-8 is professional guidance rather than consumer advertising. Plaintiffs filed a first amended complaint on August 18, 2026. The district court subsequently denied WPATH’s earlier motions to dismiss or transfer as moot and directed the defendants to respond to the amended complaint by September 8, 2026.

States challenge FTC’s theory of liability

The FTC characterizes the lawsuit as a straightforward health-claims enforcement action directed at allegedly deceptive representations used to sell services. The amici states, by contrast, that the complaint improperly recasts professional medical recommendations as consumer fraud and risks intruding on the states’ traditional authority to regulate medical practice.

According to the amici, the plaintiffs’ theory rests in part on the premise that WPATH’s guidelines benefit members who provide the recommended care. The states respond that professional societies are necessarily composed of practitioners in their fields and routinely issue guidance about services their members perform. In their view, treating that relationship as commercial inducement could expose organizations across medicine, including societies in cardiology, oncology, neurology, and pediatrics, to similar scrutiny.

The amici also emphasize the states’ police powers over professional licensure, standards of care, informed consent, and patient protection. At the time the brief was filed, each amicus jurisdiction permitted gender-affirming care for adolescents; many affirmatively protected access to such care, and several covered medically necessary gender-affirming care through their Medicaid programs. The amici argue that the FTC should not be permitted to use an enforcement action against WPATH to second-guess those state policy judgments indirectly.

Potential implications beyond gender-affirming care

The case follows a broader series of federal actions concerning pediatric gender-affirming care. Earlier initiatives largely focused on providers, federal funding, reimbursement, or participation in federal healthcare programs. Those initiatives included the Centers for Medicare & Medicaid Services (CMS) 2025 information requests to selected hospitals, and the US Department of Health and Human Services and CMS actions announced in December 2025. CMS has since finalized a rule, effective October 13, 2026, prohibiting federal Medicaid funding for specified procedures for individuals under age 18 and federal Children’s Health Insurance Program funding for specified procedures for individuals under age 19.

The WPATH case differs because it places a professional association’s development and dissemination of clinical standards at the center of the dispute. It may therefore test when statements contained in or made in connection with scientific or clinical guidance can support consumer protection liability, including as advertising claims, or as a means by which others make deceptive claims.

The amici warn that a broad ruling for the plaintiffs could create uncertainty for organizations that develop clinical guidelines, particularly where members participate in drafting recommendations or provide the services addressed by those recommendations. They also contend that the resulting uncertainty could affect medical research, public health initiatives, and state antidiscrimination policies. Those potential consequences remain contested: The FTC maintains that the case targets alleged deception, not the ordinary development of evidence-based clinical guidance.

Looking ahead

The immediate procedural question is how WPATH will respond to the amended complaint and how the court will address the parties’ competing characterizations of SOC-8. More broadly, the court’s analysis could help define the circumstances in which a professional association’s clinical standards and related communications may support consumer protection liability.

For professional societies, healthcare providers, life sciences companies, and other stakeholders, the case highlights the importance of transparent guideline-development methods, careful characterization of the strength of evidence and consensus, robust conflict-of-interest disclosures, and clear separation between clinical guidance and promotional claims. The proceedings may also signal whether federal regulators will use consumer protection law more frequently to challenge healthcare guidance that influences treatment and reimbursement decisions.